PMC3934615_01
Case 1: CEA changes demonstrate resensitization to a previously failed therapy. Time is shown as day number after the first dose of RRx-001. A: Last dose of RRx-001. B: First dose of FOLFIRI.
cro-0007-0079-g01.jpg
PMC3934615_01_cro-0007-0079-g01.jpg
F1
The principal investigator (T.R.) restarted FOLFIRI, and the patient was treated for approximately 5 months, resulting in a sharp decline in the CEA levels from 511 to 162 (fig. 1).
PMC3934615_02
CT images from case 2. Day numbers refer to the days after the first RRx-001 dose. The arrows indicate the target lesion whose change in longest diameter is shown in Figure 3. a Chest CT scan, measured at day 50 and showing stable disease. b Chest CT scan on day 186, showing an increased size of the mass in the right lung field. Dosing with RRx-001 was stopped. c Chest CT on day 228, 42 days after RRx-001 was stopped, showing a significant enlargement of the right upper lobe mass and interval nodule growth. The patient was not treated during this period. d Chest CT scan on day 256, approximately 4 weeks after treatment with FOLFIRI, was commenced, showing a modest reduction in the size of the right upper lobe mass and pulmonary lesions. e Chest CT scan on day 294, approximately 8 weeks after treatment with FOLFIRI was started, showing further tumor shrinkage.
cro-0007-0079-g02.jpg
PMC3934615_02_cro-0007-0079-g02.jpg
F2
His disease stabilized for 6 months before progressing again (fig. 2, fig. 3).